Enclomiphene and blood work: what to test and when

Last updated 2026-07-27

What blood work do you need before starting enclomiphene?

Baseline labs matter more with enclomiphene than with most TRT protocols, because the whole point of the drug is to see how your own hypothalamic-pituitary-gonadal (HPG) axis responds. If you don't know where you started, you can't tell whether it worked. A reasonable baseline panel includes total testosterone, free testosterone, LH, FSH, and estradiol (sensitive assay if your lab offers it). Many providers add a CBC (to check hematocrit and hemoglobin before treatment), a lipid panel, and liver enzymes, since SERMs are metabolized hepatically and some men see mild lipid shifts. If fertility is a real goal, more than theoretical, a baseline semen analysis is worth doing before you start anything, so you have a true before-and-after. Timing matters for testosterone draws specifically. The Endocrine Society's guideline on testosterone therapy in men recommends morning measurement, because testosterone follows a circadian rhythm and is highest between roughly 7 and 10 AM ^[1]. Draw blood at 2 PM and you can get a number that looks low even in a man responding normally to treatment. If you're working with Enclomiphene Direct dosage guidance already, your provider should be ordering these baseline labs before the first prescription, not after. One more thing worth flagging: if you've been on exogenous testosterone (TRT, not enclomiphene) recently, your baseline LH and FSH will likely be suppressed regardless of your native axis function. That's not a enclomiphene problem, it's a recent-suppression problem, and it can take weeks to months to normalize before baseline labs reflect your true starting point.

How soon after starting enclomiphene should you retest?

Most clinical protocols retest at 4 to 6 weeks after starting or after a dose change. That's the interval used in the pharmacokinetic and clinical studies of enclomiphene citrate, where testosterone and gonadotropin changes were tracked over roughly 3 to 6 months ^[2]. Here's the mechanism reason for that window: enclomiphene blocks estrogen receptors at the hypothalamus, which the brain reads as "estrogen is low," so it increases GnRH pulsing. That raises LH and FSH within days to a couple weeks. Testosterone production in the testes then ramps up in response, but it takes longer, generally 2 to 4 weeks, to show a stable rise on a blood draw. Checking labs at 1 or 2 weeks is usually too early to judge whether a dose is working. After the first follow-up panel, if numbers look reasonable and you feel fine, a lot of providers move to quarterly or twice-yearly rechecks. If your dose changes, you're back to the 4-6 week recheck clock. A rough sense of what changes and when: | Marker | Typical direction | Time to see change |

What testosterone level should you expect on enclomiphene?

There's no single target number, and anyone who gives you one without checking your baseline and symptoms is guessing. But the published data give a useful range. In a phase 2 study of enclomiphene citrate in hypogonadal men, average total testosterone rose from baseline (roughly 200-300 ng/dL range, consistent with entry criteria for hypogonadism) into the 500-600 ng/dL range over the treatment period, with most men reaching levels considered normal by standard lab reference ranges ^[2]. Individual response varies a lot based on starting testicular function, dose, and body composition. Most labs use a normal total testosterone reference range somewhere around 300 to 1000 ng/dL, though exact cutoffs vary by lab and assay. The Endocrine Society guideline suggests using the lower limit of normal for a healthy young reference population as the threshold for diagnosing low testosterone, rather than a single universal number ^[1]. Worth saying plainly: enclomiphene is not a guaranteed fix. Men with primary testicular failure (where the testes themselves can't respond to LH/FSH signal, no matter how high it goes) won't get much benefit, since the drug works by increasing pituitary signal, not by directly stimulating the testes. Blood work is what separates a true secondary hypogonadism case (where enclomiphene tends to work) from one where it won't.

How does enclomiphene affect LH and FSH, and why does that matter for fertility?

This is the whole reason enclomiphene exists as an alternative to TRT for men who care about fertility. Exogenous testosterone (injections, gels, pellets) suppresses LH and FSH because the brain senses plenty of testosterone already circulating and shuts down its own signal to produce more. Suppressed LH and FSH means suppressed intratesticular testosterone and suppressed sperm production, sometimes down to azoospermia (zero sperm count). Enclomiphene works the opposite direction. As a selective estrogen receptor modulator (SERM), it blocks estrogen receptors in the hypothalamus, which removes the negative feedback signal and increases GnRH, LH, and FSH output. Since LH and FSH are exactly what stimulate the testes to make testosterone and sperm, enclomiphene raises testosterone while, in principle, maintaining or even increasing the gonadotropin signal that fertility depends on. A study comparing enclomiphene citrate to testosterone gel in hypogonadal men found that men on testosterone gel had significant reductions in LH and FSH, while men on enclomiphene maintained LH and FSH near baseline or higher, with testosterone levels comparably raised in both groups ^[2]. That's the core evidence behind the fertility-preservation claim. But don't oversell it. "Preserving LH and FSH" and "maintaining fertility" are related but not identical to "proven to maintain or improve pregnancy rates." The clinical trial data on enclomiphene is built mostly around hormone levels and semen parameters as surrogate markers, not live birth or conception outcomes. If you're actively trying to conceive, semen analysis, more than serum hormones, is the number that should guide the conversation with your provider or a reproductive urologist.

How is enclomiphene different from clomiphene on blood work and mechanism?

Clomiphene citrate (brand name Clomid) is actually a mixture of two isomers: enclomiphene (the trans-isomer) and zuclomiphene (the cis-isomer). Enclomiphene is the isomer responsible for most of the anti-estrogenic, HPG-axis-stimulating effect. Zuclomiphene is weakly estrogenic and has a much longer half-life, lingering in the body for weeks after a dose, which is part of why some men on clomiphene report more estrogen-related side effects (mood changes, visual disturbances) than men on isolated enclomiphene ^[3]. On blood work, both drugs raise LH, FSH, and testosterone through the same basic mechanism (estrogen receptor blockade at the hypothalamus). The theoretical advantage of enclomiphene alone is less zuclomiphene accumulation and potentially fewer estrogen-driven side effects, though head-to-head long-term comparative data in humans is thinner than marketing would suggest. Some published pharmacokinetic work supports the shorter half-life and reduced zuclomiphene exposure claim ^[3], but large comparative trials on side effect rates between isolated enclomiphene and full clomiphene are limited. Regulatory status differs sharply. Clomiphene citrate is FDA-approved, but only for female infertility, not for male hypogonadism; its use in men is off-label. Enclomiphene citrate alone was studied under the brand name Androxal by Repros Therapeutics for male secondary hypogonadism, but that development program never reached FDA approval, and Repros discontinued it after acquisition ^[4]. What's sold today as enclomiphene comes from compounding pharmacies, not as an FDA-approved manufactured drug product.

Is enclomiphene FDA-approved, and does that affect how labs are used?

No. Enclomiphene citrate is not FDA-approved as a standalone product for any indication. The Androxal program, which studied enclomiphene specifically for secondary hypogonadism in men, completed multiple clinical trials but was never submitted successfully to or cleared by the FDA ^[4]. What's available today is compounded enclomiphene, prepared by a compounding pharmacy under a prescription, not a manufactured, FDA-reviewed drug product with an approved label. That has a direct, practical effect on how blood work gets used. With an FDA-approved drug, dosing guidance, monitoring intervals, and expected lab ranges come from an approved package insert built on the trials submitted to the agency. With compounded enclomiphene, there's no such document. Your provider is relying on the published trial literature (mostly the Androxal-era studies), general SERM pharmacology, and your individual lab trends to make dosing decisions. That's not necessarily worse care, but it does mean monitoring needs to be more active, not less, because there's no standardized label to fall back on. The Federal Food, Drug, and Cosmetic Act sets separate rules for compounded drugs under sections 503A and 503B, covering traditional pharmacy compounding versus larger-scale outsourcing facility production, at 21 U.S.C. 353a and 353b ^[5]. A legitimate compounding pharmacy operates under state board of pharmacy licensure and, for 503B facilities, registers with the FDA and follows current good manufacturing practice standards. Ask whoever prescribes enclomiphene which pharmacy fills it and whether that pharmacy is 503A or 503B licensed. If a source can't answer that question, that's a red flag. Enclomiphene Direct connects patients with providers who review labs before prescribing and use a named, licensed pharmacy partner to fill compounded enclomiphene, rather than shipping product with no clinical oversight attached.

What labs catch problems early on enclomiphene?

Estradiol is the one to watch most closely, ironically, given the drug's anti-estrogenic mechanism. Because enclomiphene raises LH, and LH drives testosterone production, and some of that testosterone aromatizes into estradiol, total estradiol can actually rise on enclomiphene even though the drug is blocking estrogen receptors at the hypothalamus specifically. Elevated estradiol without matching symptom relief is one reason some men feel "off" on enclomiphene despite good testosterone numbers. Hematocrit and hemoglobin matter too, though less dramatically than with injectable testosterone. Because enclomiphene raises endogenous testosterone rather than delivering supraphysiologic exogenous doses, polycythemia (elevated red blood cell count) tends to be less common than with TRT, but it's not zero risk, especially in men who reach high-normal or above-range testosterone. A CBC at baseline and at follow-up catches this. Liver enzymes (AST/ALT) are worth a baseline check and an occasional recheck, since SERMs are hepatically metabolized, though clinically significant liver toxicity from enclomiphene at standard doses isn't a commonly reported problem in the trial literature. Mood and vision changes are not blood tests, but they're part of monitoring. Clomiphene (and by extension, its enclomiphene component) carries a well-documented, if uncommon, association with visual disturbances, and any new visual symptom warrants stopping the drug and calling your provider immediately, not waiting for the next lab draw.

How long should you stay on enclomiphene, and does that change monitoring?

There's no universally agreed max duration in the literature, since enclomiphene alone was never approved and long-term (multi-year) trial data doesn't exist the way it does for testosterone replacement. The Androxal-era trials generally ran 3 to 6 months ^[2]. Beyond that window, you're in territory guided by ongoing labs and symptom response rather than trial-proven duration. Practically, a lot of providers treat enclomiphene as a longer-term maintenance therapy for secondary hypogonadism, similar to how they'd manage TRT, provided labs stay in range and side effects stay minimal. Others use it in shorter, defined cycles, particularly men who alternate between fertility-focused windows and periods where fertility isn't an immediate concern. If you're mapping out how long a given course should run, Enclomiphene Direct cycle length covers how providers typically structure that decision. Either way, the monitoring rhythm doesn't really change with duration. Recheck 4-6 weeks after any dose change, then settle into quarterly or semiannual labs once stable. Long-term users should keep an eye on the same panel (testosterone, LH, FSH, estradiol, CBC) indefinitely, more than during the first few months.

What does the dosing process actually look like with lab monitoring built in?

A reasonable enclomiphene protocol, built around lab checkpoints, looks something like this: baseline panel and symptom review, prescription start (commonly in the 12.5 to 25 mg daily range, though your provider sets the actual number based on your baseline), recheck at 4-6 weeks, dose adjustment if needed, then a second recheck 4-6 weeks after any adjustment, then quarterly monitoring once stable. Dose and reconstitution specifics (for injectable or compounded oral formats) are covered in more detail at Enclomiphene Direct dosage and, if you're using a calculator to figure out concentration and volume, Enclomiphene Direct dosage calculator. If your formulation requires reconstitution before use, how to reconstitute Enclomiphene Direct walks through that process, and injection technique and site rotation are covered at Enclomiphene Direct how to inject and Enclomiphene Direct injection sites. The main point worth repeating: none of that dosing information replaces a lab-driven decision. Compounded medication without a package insert means the lab draw is effectively your safety net and your evidence that the dose is doing what it's supposed to.

Frequently asked questions

How often should you get blood work while on enclomiphene?

Most protocols call for a recheck 4-6 weeks after starting or after any dose change, since testosterone and gonadotropin levels take several weeks to stabilize. Once labs look stable and symptoms are controlled, many providers move to quarterly or twice-yearly monitoring. Any new dose adjustment restarts the 4-6 week recheck clock.

Does enclomiphene show up differently than testosterone on a blood test?

Yes. Enclomiphene raises your own LH, FSH, and testosterone, so a blood panel shows elevated or normal LH/FSH alongside rising testosterone. Exogenous TRT suppresses LH and FSH while raising testosterone directly. That LH/FSH pattern is the main lab signature distinguishing enclomiphene use from injectable or gel testosterone.

What testosterone level is considered normal on enclomiphene?

There's no single enclomiphene-specific target. Providers generally aim for the normal reference range used for diagnosing hypogonadism, often cited around 300 to 1000 ng/dL depending on the lab's assay, with symptom improvement weighed alongside the number rather than treating the number alone as success.

Can enclomiphene raise estradiol on blood work?

Yes, sometimes. Enclomiphene blocks estrogen receptors at the hypothalamus, but the testosterone it stimulates can still aromatize into estradiol elsewhere in the body, so total estradiol on a blood panel can rise even as the drug exerts anti-estrogenic effects centrally. That's why estradiol is worth tracking, not assuming it will fall.

Is enclomiphene the same thing as clomiphene?

No. Clomiphene citrate (Clomid) is a mixture of two isomers, enclomiphene and zuclomiphene. Enclomiphene drives most of the testosterone-raising effect; zuclomiphene is weakly estrogenic with a much longer half-life. Enclomiphene alone is meant to isolate the more useful isomer, though it was never FDA-approved as a standalone drug.

Is enclomiphene FDA-approved?

No. Enclomiphene citrate alone was studied under the name Androxal for male secondary hypogonadism, but that program never reached FDA approval and was discontinued. What's available today is compounded enclomiphene from a licensed compounding pharmacy, prescribed off-label under a provider's clinical judgment, not an FDA-approved manufactured drug.

Does enclomiphene preserve fertility better than TRT?

The evidence points that direction on hormone markers: studies show enclomiphene maintains or raises LH and FSH while testosterone gel suppresses both. That supports a fertility-preservation rationale, but large trials measuring actual pregnancy or live birth outcomes on enclomiphene are limited, so treat it as a mechanistically sound, evidence-supported option rather than a guaranteed fertility outcome.

How long does it take for LH and FSH to rise after starting enclomiphene?

LH and FSH typically begin rising within 1 to 2 weeks of starting enclomiphene, since the drug's effect on hypothalamic estrogen receptors happens quickly. Testosterone follows over the next 2 to 4 weeks as the testes respond to the increased signal, with levels generally stabilizing by around 6 weeks.

Do you need a semen analysis while on enclomiphene?

If fertility is an active goal, yes, a baseline semen analysis before starting and a follow-up at 3 months or later gives a real answer, since sperm production takes roughly 64 to 74 days from start to finish. Blood hormone levels alone don't confirm sperm count or quality.

What blood tests should be done before starting enclomiphene?

A solid baseline panel includes total testosterone, free testosterone, LH, FSH, and estradiol, drawn in the morning when testosterone peaks. Many providers add a CBC, lipid panel, and liver enzymes. If fertility is a goal, a baseline semen analysis before starting gives a true comparison point later.

Can enclomiphene cause high hematocrit like TRT does?

It's less common than with injectable TRT, since enclomiphene raises testosterone into a physiologic range through your own production rather than delivering supraphysiologic exogenous doses. But it's not zero risk, particularly in men who reach high-normal testosterone, so a baseline and follow-up CBC checking hematocrit and hemoglobin is still reasonable.

Who compounds enclomiphene, and is that legal?

Enclomiphene is compounded by licensed pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which set rules for compounding based on an individual prescription or, for 503B outsourcing facilities, larger-scale production under current good manufacturing practice standards. It's legal when prescribed by a licensed provider and filled by a properly licensed pharmacy.

Sources

1. Endocrine Society, Testosterone Therapy in Men with Hypogonadism Clinical Practice Guideline: Morning blood draw and reference range recommendations for diagnosing and monitoring testosterone therapy
2. Kim et al., 'Enclomiphene citrate rises testosterone while maintaining sperm production' comparative study: Enclomiphene versus testosterone gel effects on LH, FSH, and testosterone levels in hypogonadal men
3. Kim et al., pharmacokinetics of enclomiphene and zuclomiphene isomers: Half-life and estrogenic activity differences between enclomiphene and zuclomiphene isomers of clomiphene
4. Repros Therapeutics SEC filing / FDA correspondence on Androxal (enclomiphene) program discontinuation: Androxal (enclomiphene citrate) development program did not reach FDA approval and was discontinued
5. 21 U.S.C. 353a and 353b, Federal Food, Drug, and Cosmetic Act provisions on pharmacy compounding and outsourcing facilities: Legal framework under the Federal Food, Drug, and Cosmetic Act governing compounding pharmacies and outsourcing facilities